A variety of HSP90 inhibitors have been investigated for CML therapy, including geldamamycin (GA) derivatives and radicicol (RD) [18, 19]. The gene discussed is HSP90AA1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.